The number of patients with chronic wounds has increased over the past several decades alongside a dramatic increase in type 2 diabetes. NCBI estimates 2% of the total population of developed nations will experience a chronic wound in their lifetime. Diabetic Foot Ulcers (DFUs) progress quickly to problem wounds due to microvascular changes associated with diabetes. They are notoriously difficult to treat. Poor blood circulation compromises oxygen flow and, as a result, can quickly become infected. Ultimately, wounds that are not able to heal are treated by amputation. Annual incidences of foot ulcers among people with diabetes are approximately 7%, and annual incidences of amputation resulting from these wounds are approximately 0.25% to 1.8%. Untreated, or poorly treated wounds are unfortunately prevalent, leading to costly procedures, hospitalizations, and a need for rehabilitation. Oxymend™ aims to provide patients with chronic wounds greater access to care by developing an affordable, wearable, efficacious, miniaturized oxygen production and delivery dressing - outperforming Hyperbaric Oxygen Therapy in a device that could fit in your pocket.